Beyond their prognostic impact, the RAS/RAF/MEK/ERK pathway alterations appear implicated in the mechanisms of sensitivity and resistance to a vast array of drugs, with relevance for all breast cancer subtypes. Here, RAF1 is linked to breast carcinoma.